Company’s 36-month beta value is 1.41.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OCUL is 133.71M, and currently, short sellers hold a 10.34% ratio of that floaft. The average trading volume of OCUL on June 04, 2025 was 1.78M shares.
OCUL) stock’s latest price update
The stock price of Ocular Therapeutix Inc (NASDAQ: OCUL) has surged by 2.71 when compared to previous closing price of 8.11, but the company has seen a 20.03% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-14 that BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
OCUL’s Market Performance
OCUL’s stock has risen by 20.03% in the past week, with a monthly drop of -5.34% and a quarterly rise of 28.15%. The volatility ratio for the week is 2.13% while the volatility levels for the last 30 days are 4.73% for Ocular Therapeutix Inc The simple moving average for the last 20 days is 11.97% for OCUL stock, with a simple moving average of -1.51% for the last 200 days.
Analysts’ Opinion of OCUL
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $17. The rating they have provided for OCUL stocks is “Outperform” according to the report published on March 18th, 2025.
Needham gave a rating of “Buy” to OCUL, setting the target price at $15 in the report published on March 11th of the current year.
OCUL Trading at 11.83% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.26% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUL starting from Waheed Nadia, who sale 13,861 shares at the price of $8.05 back on Jun 02 ’25. After this action, Waheed Nadia now owns 206,805 shares of Ocular Therapeutix Inc, valued at $111,581 using the latest closing price.
NADIA K. WAHEED, the Officer of Ocular Therapeutix Inc, proposed sale 13,861 shares at $8.05 during a trade that took place back on Jun 02 ’25, which means that NADIA K. WAHEED is holding shares at $111,524 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.91 for the gross margin
The net margin for Ocular Therapeutix Inc stands at -3.23. The total capital return value is set at -0.55. Equity return is now at value -57.19, with -40.79 for asset returns.
Based on Ocular Therapeutix Inc (OCUL), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.91. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -31.2.
Currently, EBITDA for the company is -176.14 million with net debt to EBITDA at 1.52. When we switch over and look at the enterprise to sales, we see a ratio of 17.68. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.22.
Conclusion
In a nutshell, Ocular Therapeutix Inc (OCUL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
